x 

0 Activities
0 Activities
    • No Saved Activities

Pulmonary Hypertension (PH/PAH)

  2. Home
  3. Education
  4. Top Disease Areas
  5. Pulmonary Hypertension (PH/PAH)
  6. Specialty Area
Page 4 of 5
Results 451 - 600 of 626
curesma19-icon
The Changing Landscape of SMA–Updates from Anaheim, CA
9915-mod2-icon
A History of Hemophilia Treatment: Factor Replacement to Gene Therapy
9915-mod1-icon
Getting to Know Gene Therapy: Terminology and Concepts
9837-coolidge
What if President Calvin Coolidge Was Your Asthma Patient?
9840-0003
Optimizing Management of IPF
New_Concepts_in_the_Pathobiology_of_Asthma_264x150
New Concepts in the Pathobiology of Asthma
9916-king
What are the Most Exciting Things Happening in Pulmonary Disease?
No image set
When Is a Cough Not Just a Cough?
No image set
Diagnosing ILDs Such as IPF and More
No image set
Beyond the Basics: Complex ILD Cases
No image set
PowerPoint Slides: Achieving Better Control of Severe Asthma
9837-roosevelt
How Would You Manage President Theodore Roosevelt’s Asthma Today?
No image set
Updates in Atopic Dermatitis: The Allergist’s Guide to Optimizing Care - Child
No image set
Updates in Atopic Dermatitis: The Allergist’s Guide to Optimizing Care - Adult
9916-scholand
New Tools to Improve the Diagnosis of IPF vs Other ILDs
9916-brown
New Research on Therapies for Patients with Pulmonary Fibrosis
9916-richeldi
The SENSCIS Trial: Exciting News for Scleroderma-Associated ILD
9916-cc-cme
2019 Summer Pulmonary Updates: The Experts Weigh In
No image set
U.S. Presidents with Severe Asthma: Endotypes and Precision Medicine
9833-0001-icon
Urgency for Early Diagnosis and Treatment of SMA
sma-journal-icon_263x0
Gene Therapy for SMA: An Emerging Treatment Option for a Devastating Disease
No image set
Reporting HRCT Findings for ILD from a Multidisciplinary Team
med-doc-aatd
A Closer Look at Alpha-1 Antitrypsin Deficiency: Peggy’s Story
med-doc-ph
How Pulmonary Arterial Hypertension Has Changed Iain’s Life
9834-0002
SMA: Data, Insights and Practice
9829-0001
From Bench to Bedside: Gene Therapy Approaches for Rare Diseases
hopa-icon8
Biosimilars: Applying the Science to Hematology/Oncology Practice
9819-ntm case3
Management of Mycobacterium Abscessus Lung Disease
9819-ntm case2
Difficult to Treat Mycobacterium Avium Complex Lung Disease
9819-ntm case1
Management of Mycobacterium Avium Complex Lung Disease
9816-0001
The Latest from a Recent Pulmonary Conference in San Antonio
9816-0010
Updates in Inoperable CTEPH
9816-0009
The Importance of Early Integration of Palliative Care
9816-0006
Management of IPF Patients in 2018
9816-0005
Updates in the Diagnosis of ILD and the Role of Cryobiopsy
9816-00045
Overview of the Latest Clinical Trials in IPF
9816-0003
Evolution of Antifibrotic Therapy in IPF
9816-0002
Take Home Messages from the 2018 CHEST Annual Meeting
9816-0008
What We’re Learning from the IPF-PRO Registry
9816-0007
Comparing the 2017 Fleischner Society Guidelines and the 2018 ATS Guidelines
rePlace2
Emerging Treatments for NTM Lung Disease
rePlace2
Nontuberculous Mycobacteria Case 2: Alan
NTM_and_Treatment_Strategies_for_Patients_264x150
NTM and Treatment Strategies for Patients with Cavitary Disease
New_Findings_in_the_Treatment_of_MAC_264x150
New Findings in the Treatment of MAC Lung Disease
Why_You_Should_Pay_Attention_to_NTM_264x150
Why You Should Pay Attention to NTM Treatment Guidelines
Which_of_Your_Patients_Are_at_Risk_for_NTM_264x150
Which of Your Patients Are at Risk for NTM?
Practice_Improvement_through_ILD_Centers_264x150
Practice Improvement through ILD Centers and Community Partnerships
Improving_the_Care_for_IPF_Patients_264x150
Improving the Care for IPF Patients Using a Team-Based Approach
An_Early_Integrated_Palliative_Care_264x150
An Early Integrated Palliative Care Delivery Model for Patients with IPF
rePlace2
Treatment Challenges with MAC Lung Disease
rePlace2
Nontuberculous Mycobacteria: Summary
rePlace2
Treatment Challenges with MABC Lung Disease
rePlace2
Nontuberculous Mycobacteria Case 1: Maria
rePlace2
NTM – To Treat or Not to Treat
rePlace2
Goals of NTM Treatment
rePlace2
Guideline-recommended Treatments for NTM
rePlace2
Diagnosis of NTM
rePlace2
Factors Associated with Respiratory Involvement in NTM
rePlace2
Most Common Species in NTM Lung Disease
rePlace2
Nontuberculous Mycobacteria: Introduction and Epidemiology
9808-0004
What’s New in Spinal Muscular Atrophy? Reporting from Dallas
atopic-derm4
Atopic Dermatitis: Putting it Together (Dermatology)
atopic-derm3
Atopic Dermatitis: Putting it Together (Primary Care)
atopic-derm2 copy
Atopic Dermatitis: Recent and Emerging Therapies
atopic-derm1
An Introduction to Atopic Dermatitis
No image set
New Therapies, New Opportunities and New Challenges in Managing NTM
No image set
Updates in Inoperable CTEPH
9808-0003
SMA Updates from Los Angeles
pah icon
PAH Today: Mastering Current, Tailored Treatment
No image set
Achieving Better Control of Severe Asthma
asthma-uncontrol icon
A Personalized Approach to Managing Uncontrolled Asthma
9808-0002
Updates in SMA and Gene Therapy from Arlington, VA
Proper_Use_of_an_Inhaler_264x150
Proper Use of an Inhaler
biosims-archmed icon23
Top Questions about Biosimilars in Dermatology
biosims-archmed icon1
Top Questions about Biosimilars in Gastroenterology
biosims-archmed icon2
Top Questions about Biosimilars in Rheumatology
biosims-archmed icon
Top Questions about Biosimilars in Hematology/Oncology
biosims-gastro2
Biosimilars and Patients with Inflammatory Bowel Disease
No image set
Nontuberculous Mycobacterial Lung Disease Today and Tomorrow
No image set
Exploring the Patient Journey with Problem-Based Learning
No image set
Genetics and Personalized Medicine for Patients with Pulmonary Fibrosis
No image set
Environmental Influences on the Development of Pulmonary Fibrosis
No image set
Gene Abnormalities and ILD
No image set
Exploring the Basic Mechanisms that Contribute to Development of Lung Fibrosis
No image set
Updates on Registry Enrollment and Growth of the Care Center Network
No image set
New Approaches to the Diagnosis of IPF
No image set
Exploring New Therapeutic Avenues for Managing PF
No image set
New Research on Mechanisms in the Development of PF
biosims-gastro1
Biosimilars: The New Era of Gastroenterology Management Considerations
No image set
Know Before You Go: IPF Grand Rounds Pre-learning
No image set
IPF Management Considerations
No image set
Perspectives on Side Effect Management
No image set
The Latest in IPF: Implications for Clinical Practice
No image set
Registry Data Provide Important Severity Indicators for PH
No image set
New Developments in the Diagnosis and Management of IPF
No image set
Palliative Care for Patients with IPF
No image set
Real World Experience in Patients with COPD
No image set
ICD-10 Codes and Nomenclature for Classification of PAH
No image set
Fleischner Society Update in Classification of IPF
No image set
Transbronchial Cryobiopsy for the Diagnosis of ILD
psoriasis-nurse
Psoriasis Management Considerations: What Would You Do?
psoriasis-case3
Jamie Develops Complications with Her Psoriasis
psoriasis-case2
Psoriasis: Three Case Studies in the Primary Care Setting
psoriasis-case1
Cindy Has a Complex Case of Psoriasis
No image set
Optimizing Patient Outcomes in IPF
No image set
Understanding IPF as a Part of the Overall Scope of ILD
9707-ella
Famous People with Diabetes: Ella Fitzgerald
9707-jerry
Famous People with Diabetes: Jerry Garcia
aims icon-target
Targeting B-cells in Primary Progressive MS (PPMS)
aims icon-comorb
Comorbidities and Selection of DMTs
aims icon-gut
The Gut Microbiota in MS
aims icon-early
Early MS: Induction Therapy and Escalation Strategies
aims icon-vitamin
Vitamin D: Modifiable Risk Factor and its Role in the Management of Patients with MS
t2diabetes-slides1
Download Slides: Optimizing Diabetes Treatment in a Sea of Treatment Options
No image set
The Importance of Early Referral and Treatment
No image set
How to Recognize and Diagnose IPF
No image set
What Is IPF?
No image set
What’s Next for IPF Therapy?
No image set
Applying the Evidence on Antifibrotic Agents for IPF
No image set
What Do the Experts Say about New Developments in the Diagnosis of ILD?
No image set
Is the delivery system a good match for your patients with COPD?
No image set
Stepping up or stepping down – which direction for COPD patients?
No image set
What’s the 2017 GOLD standard for managing patients with COPD?
No image set
UIP, IPF, NSIP, CHP: Making Sense of the Letters
t2diabetes-slides2
Download Slides: Advancing T2DM Therapy with Confidence
t2diabetes-louise
Getting to Goal Can Be Difficult: Louise
t2diabetes-brian
Getting to Goal Can Be Difficult: Brian
No image set
A Personalized Approach to Managing Patients with Uncontrolled Asthma
IL-rheum-case3
Considering Biosimilars in Patients Failing their Initial Biologic
IL-rheum-case2
When to Switch? Biologically Experienced Patients with Spondyloarthritis
IL-rheum-case1
Innovator or Biosimilar for a Patient with Rheumatoid Arthritis
IL-gastro-case3
Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?
IL-gastro-case2
Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic
IL-gastro-case1
Innovator or Biosimilar for a Patient with Ulcerative Colitis?
IL-derm-case3
Switching Between Biologics: Is a Biosimilar an Option?
IL-derm-case2
When to Switch? Biologically Experienced Psoriasis Patients
IL-derm-case1
Innovator or Biosimilar for a Patient with Psoriasis
IL-fund-case4
Interchangeability and Pharmacy-Level Substitution
IL-fund-case3
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
IL-fund-case2
What is the Difference Between a Biosimilar and a Generic?
IL-fund-case1
What is a Biologic?
No image set
New Strides in EGFR Inhibition for Non–Small Cell Lung Cancer
No image set
Pete - Work-Up of a Patient with Right Upper Lobe Mass and Metastases
No image set
Carl - High Suspicion of Lung Cancer: Setting the Stage with a Good Biopsy
biosims-full
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
biosims-green5
Are You Ready to Use Biosimilars in Your Practice?
biosims-full3
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
biosims-green3
Pharmacovigilance and Biosimilars: Any Special Considerations?
biosims-full5
Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
biosims-green8
Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?
Page 4 of 5

Search